Streetbeat News

Equity Actions

RXST

Analysts have recently updated their ratings and price targets for RxSight (NASDAQ:RXST), showing a mix of bullish and somewhat bullish opinions. The average 12-month price target has been raised to $47.44, indicating a positive outlook. Key financial indicators reveal RxSight's strong revenue growth but challenges in profitability and asset utilization. The company, focusing on intraocular lens technology post-cataract surgery, shows a positive revenue trend but struggles with net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:00 pm

MSFT

NVDA

Figure AI announced it has raised $675 million at a valuation of $2.6 billion and signed a collaboration agreement with OpenAI. The funding round includes investments from Microsoft, OpenAI Startup Fund, Nvidia, and Jeff Bezos.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:59 pm

APP

AppLovin announced the pricing of a secondary offering of 19,866,397 shares of its Class A common stock by KKR Denali Holdings L.P., clarifying that it will not receive any proceeds from the sale.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:50 pm

PNW

Pinnacle West Capital has announced the pricing of its registered public offering of 9,774,436 shares of its common stock, aiming to raise approximately $630.5 million in net proceeds.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:32 pm

MIST

Milestone Pharmaceuticals announced the pricing of its public offering of 16.7 million shares at $1.50 per share and pre-funded warrants to purchase 3.3 million shares at $1.49 per pre-funded warrant, aiming to raise approximately $30 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:18 pm

AMRN

Amarin Corporation has announced the initiation of a shareholder approval process for a share repurchase program, aiming to buy back up to $50 million worth of shares by the end of Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:16 pm

RNA

Avidity Biosciences announced a $400M private placement of 15.2M shares at $16.50/share and pre-funded warrants to purchase 9.0M shares at $16.499/pre-funded warrant. This financial move is expected to extend the company's cash runway into late 2026.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:09 pm

BBWI

Bath & Body Works projects FY24 revenue to be between $7.20B and $7.43B, slightly below the $7.45B estimate, and EPS to range from $3.00 to $3.35, near the $3.34 estimate. The forecast includes a decline of up to 3% from FY23's $7.429B in net sales, partly due to the extra week in FY23. The company plans to spend approximately $300 million on share repurchases.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:08 pm

BECN

Beacon Roofing Supply (NASDAQ:BECN) has been analyzed by 4 financial analysts, showing a mix of bullish to bearish sentiments. Recent ratings include 1 bullish, 3 somewhat bullish, and an average 12-month price target of $108.5, up 7.69% from the previous target. Analyst actions from firms like Baird, JP Morgan, and Stifel indicate adjustments in ratings and price targets, reflecting evolving market conditions and company performance. Despite the positive analyst outlook, Beacon Roofing Supply faces challenges such as below-industry average market capitalization, revenue growth, net margin, ROE, and ROA, but maintains a healthier debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 12:00 pm

CRM

Analyst ratings for Salesforce (CRM) have shown a mix of sentiments, with recent updates indicating a positive shift in price targets. The average 12-month price target has risen by 9.21% to $307.0, with analysts from firms like Piper Sandler, Citigroup, and Morgan Stanley adjusting their ratings and targets. Salesforce's financial performance shows a revenue growth of 11.27% but faces challenges with net margin, ROE, and ROA below industry averages. The company's market capitalization and balanced debt approach indicate strong confidence and market prominence.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 12:00 pm